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Superoxide and H2O2 are important in redox signaling, disease and
aging. However, there are ten sites associated with the mitochondrial
respiratory chain that are known to produce these species at mea-
surable rates, making it hard to assess the contribution of particular
sites in cell physiology or pathology. We have deﬁned the maximum
capacities and many kinetic aspects of each site in skeletal muscle
mitochondria. In order of capacity they are sites IIIQo in complex III; IQ
and IIF in complexes I and II; OF, PF and BF in the 2-oxoglutarate,
pyruvate and branched chain 2-oxoacid dehydrogenase complexes; GQ
in mitochondrial glycerol phosphate dehydrogenase (mGPDH); IF in
complex I; EF in ETF/ETF:Q oxidoreductase and DQ in dihydroorotate
dehydrogenase. By screening libraries of small molecules against these
sites, we identiﬁed a novel suppressor of superoxide/H O production
at site IQ that does not affect oxidative phosphorylation (CN-POBS), and
a novel inhibitor of mGPDH (iGP-1). The rate of superoxide/H2O2
production at any site depends on its redox state, which can be
measured for sites IIIQo and IF. Therefore, we can assess the rates from
these sites in complex substrate mixes in different conditions. Using
speciﬁc inhibitors with correction for changes at sites IIIQo and IF,
and by measuring the suppression of signal by CN-POBS, the rates from
all signiﬁcant sites can be estimated. In this way we analyzed the rates
of superoxide/H2O2 production from different sites in mitochondria
oxidizing conventional substrates. The overall rates differed tenfold
and, importantly, the contribution of each site varied with substrate;
e.g. with succinate, most of the signal was from site IQ, with a little from
IF and IIIQo, whereas with glutamate +malate, it was shared between
sites IF, IIIQo and OF. In a complex mix of substrates mimicking resting
muscle cytosol, the major contributors were sites IQ and IIF, with
smaller contributions from IF, IIIQo and maybe EF and GQ. In a medium
mimicking contracting muscle at about 30% VO2max the overall rate
was ﬁvefold lower and site IF was dominant, with smaller contributions
from IQ, IIF, IIIQo and maybe EF, PF and GQ. These results highlight the
sites that may operate in intact muscle at rest and during exercise. This
new suite of approaches revolutionizes our ability to assess and control
production of superoxide and H2O2 from speciﬁc mitochondrial sites
that are important in physiology and pathology.
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Cancer is a complex disease in which abnormal cells divide without
control and are able to invade other tissues. However, a most relevant
phenotypic trait of cancer cells is the reprogramming of cellular
metabolism to an enhanced aerobic glycolysis to satisfy the demand
of carbon skeletons and energy that is required to sustain proliferation.
Mitochondria are essential organelles in promoting rewiring of metab-
olism during proliferation. An additional aspect in which mitochondria
are also critical organelles is in deciding and executing cell death, a
trait that is also altered in cancer cells. Cell death is molecularly and
functionally integrated with the bioenergetic function of the organelle.
A critical hub in the reprogramming of energy metabolism and cell
fate is the mitochondrial H+-ATP synthase, the engine that synthesizes
most of the ATP that sustains cellular activity of the normal dif-
ferentiated cell and that also forms part of the molecular machinery
required to execute apoptosis. Two main mechanisms are used by
human carcinomas of the breast, colon and lung to silence the H+-ATP
synthase. One is the translation masking of the mRNA that encodes
the catalytic subunit of the H+-ATP synthase (β-F1-ATPase) which is
mediated by RNA binding proteins that upon binding onto the mRNA
impede its efﬁcient translation. A secondmechanism involves the over-
expression of the ATPase Inhibitory Factor 1 (IF1), a short-lived protein
that by inhibiting the H+-ATP synthase not only contributes to
metabolic rewiring but also retrograde signals to the nucleus of the
cancer cell features of the oncogenic phenotype. In this presentation
we will summarize these ﬁndings to further emphasize the tumor
suppressor role of mitochondrial oxidative phosphorylation, a promis-
ing new therapeutic target of cancer.
doi:10.1016/j.bbabio.2014.05.225
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In organisms where they are found, the alternative respiratory
chain enzymes provide a potential buffer of oxidative stress and
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other pathological manifestations, under conditions where the oxi-
dative phosphorylation system is limiting or unavailable e.g. due
to inhibition by toxins, metabolic overload or genetic ablation of
one or more of its components. The alternative enzymes are non-
proton-motive, and are typically composed of just a single
polypeptide, in contrast to the highly complex enzymes of the
oxidative phosphorylation system. Vertebrates lack the alternative
enzymes, leading to the idea that we could alleviate respiratory
chain dysfunction such as those which occurs in pathological states,
by expressing genes for these enzymes therapeutically or even
prophylactically in humans. To this end, we have set about
transferring the relevant genes to model organisms, using as our
source material the urochordate Ciona intestinalis, a representative
of the group of organisms phyletically closest to the vertebrates,
but which has retained the alternative enzymes over the course of
evolution. The Ciona alternative oxidase (AOX) can be expressed in
both Drosophila and the mouse throughout the life cycle and across
a wide range of tissues. Under standard conditions, it contributes
hardly at all to mitochondrial electron ﬂow, does not interfere with
the oxidative phosphorylation system, and appears to cause no
signiﬁcant deleterious effects. However, under stress conditions,
including both acute and chronic exposures to respiratory toxins,
genetic deﬁciency of cytochrome oxidase, or treatments that create or
potentiate overproduction of ROS, AOX can alleviate pathological
phenotypes in cells, ﬂies and in mice. If safe and efﬁcient delivery of
AOX can be achieved, it has enormous potential as a wide-spectrum
therapy for conditions associatedwith primary or secondarymitochon-
drial dysfunction.
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We have established the genotype–phenotype correlations for
the complete spectrum of POLG syndromes, by reﬁning our pre-
viously described protocol for mapping pathogenic mutations in the
human POLG gene to functional clusters in the catalytic core of the
mitochondrial replicase, Pol γ. We assigned 136 mutations to ﬁve
clusters and identify segments of primary sequence that can be used
to delimit the boundaries of each cluster. We report that compound
heterozygous patients with two mutations from different clusters
manifested more severe, earlier onset POLG syndromes, whereas two
mutations from the same cluster are less common and generally are
associated with less severe, later onset POLG syndromes. We also
show that speciﬁc cluster combinations are more severe than others,
and have a higher likelihood to manifest at an earlier age. Our
clustering method provides a powerful tool to predict the pathogenic
potential and predicted disease phenotype of novel variants and muta-
tions in POLG, the most common nuclear gene underlying mitochon-
drial disorders. We propose that such a prediction tool would be useful
for routine diagnostics for mitochondrial disorders.
doi:10.1016/j.bbabio.2014.05.227
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Reactive oxygen species (ROS) are toxic to the cells and theremust be
speciﬁc defense mechanism in the cells to alleviate oxidative stress. The
primarily responsible enzyme for this reaction is the Alkylhydroperoxide
Reductase (AhpR) enzyme, consisting of the 57 kDa ﬂavo protein AhpF
(PrxR) expressed only by eubacteria and the 21 kDa AhpC (Prx) protein
expressed in all kingdoms [1,2]. The reduction of peroxides occurs via
the redox active disulphide center of AhpC, whose reduced state
becomes restored by AhpF, which transfers electrons from NADH onto
AhpC. AhpF consists of three domains; thioredoxin (Trx) like N-terminal
domain (NTD) attached to the thioredoxin reductase (TrxR) like C-
terminal portion containing FAD- and NADH-binding domains. The
proposed catalytic turnover of AhpFmay requiremajor domainmotions,
analogous to those deduced from bacterial Trx/TrxR system [3]. Here we
are presenting for ﬁrst time the crystal structure of E. coli AhpF complex
with its substrate NADH at 2.5 Å resolution [4]. The structure reveals
the basis of its substrate speciﬁcity for NADH over NADPH. In addition,
it implies the alternating conformation required for the C-terminal
NADH-binding domain to bring a bound NADH to the re-face of the
isoalloxazine ring of ﬂavin, and enabling the electron transfer to occur as
well as the oxidation of NADH-domain dithiol via the redox active
disulphide centre of the NTD. The detailed structural model will open
future research opportunities to design selective drug against bacterial
AhpF as potential target.
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